Clinical Trial

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-05; most recent amendment 2025-07-22.
Status change: Not Yet Recruiting → Recruiting 2024-03-05
Trial Details
NCT Number NCT06208410
Lead Sponsor Risen (Suzhou) Pharma Tech Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 306 participants
Start Date 2024-01-11
Primary Completion 2027-02-26 (estimated)
Study Completion 2027-02-26 (estimated)
Updated on ClinicalTrials.gov 2025-07-25